ABUS联合血清VEGF、CEA对乳腺癌的诊断价值

doi:10.3760/cma.j.issn.1007-1245.2024.05.007

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (5): 740-743.DOI: 10.3760/cma.j.issn.1007-1245.2024.05.007

ABUS联合血清VEGF、CEA对乳腺癌的诊断价值

田燕¹ 袁权¹ 王虎霞² 惠金子³ 段绍雪¹

¹陕西省肿瘤医院超声科，西安　710061；²陕西省肿瘤医院乳腺二科，西安　710061；³陕西省肿瘤医院核医学科，西安　710061

收稿日期:2023-11-23 出版日期:2024-03-01 发布日期:2024-03-28
通讯作者: 段绍雪，Email：mitious@163.com
基金资助:
陕西省卫生健康科研基金（2022A010）

Value of ABUS combined with serum VEGF and CEA in diagnosis of breast cancer

Tian Yan¹, Yuan Quan¹, Wang Huxia², Hui Jinzi³, Duan Shaoxue¹

¹Department of Ultrasound, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China; ²Second Department of Breast, Shaanxi Provincial Cancer Hospital, Xi'an 710061, China; ³Department of Nuclear Medicine, Shaanxi Provincial Cancer Hospital, Xi 'an 710061, China

Received:2023-11-23 Online:2024-03-01 Published:2024-03-28
Contact: Duan Shaoxue, Email: mitious@163.com
Supported by:
Health Scientific Research Fund in Shaanxi (2022A010)

摘要/Abstract

摘要：

目的　探讨自动乳腺全容积成像诊断系统（ABUS）联合血清血管内皮生长因子（VEGF）、癌胚抗原（CEA）对乳腺癌的诊断价值。方法　选取2020年4月至2023年4月陕西省肿瘤医院收治的210例乳腺癌患者纳入观察组，年龄（52.01±5.16）岁，左侧113例，右侧97例；另选取同期100例健康体检人员纳入对照组，年龄（51.23±5.03）岁，行双侧检查。根据ABUS成像观察超声特征，分别采用酶联免疫吸附试验及化学发光法检测两组研究对象的血清VEGF、CEA水平，统计学方法采用t检验、χ²检验，并采用受试者操作特征曲线（ROC）分析ABUS联合血清VEGF、CEA对乳腺癌的诊断价值。结果　观察组虫蚀征（82.86%，174/210）、汇聚征（76.19%，160/210）、星芒征（77.62%，163/210）发生率均高于对照组（23.00%，23/100）、（20.00%，20/100）、（13.00%，13/100），差异均有统计学意义（t=104.778、87.840、115.262，均P<0.001）。观察组血清VEGF、CEA水平均高于对照组［（141.20±17.23）ng/L比（112.81±14.14）ng/L、（8.76±2.92）μg/L比（3.51±1.17）μg/L］，差异均有统计学意义（t=14.335、17.312，均P<0.001）。ROC分析显示，ABUS联合血清VEGF、CEA对乳腺癌的诊断价值最高（AUC=0.981），预测灵敏度、特异度分别为92.4%、97.0%，均高于任一单项检测。结论　ABUS联合血清VEGF、CEA检测对乳腺癌具有高度的诊断价值，相较于单一检测方法，其灵敏度和特异度都有显著提高，可以有效提升乳腺癌的早期发现和诊断准确率。

关键词:

乳腺癌, 自动乳腺全容积成像诊断系统, 血管内皮生长因子, 癌胚抗原, 诊断价值

Abstract:

Objective　To explore the value of the automated breast ultrasound system (ABUS) combined with vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in the diagnosis of breast cancer. Methods　From April 2020 to April 2023, 210 patients with breast cancer from Shaanxi Provincial Cancer Hospital were selected as an observation group, including 113 cases on the left side and 97 cases on the right side; they were (52.01±5.16) years old. One hundred healthy individuals undergoing physical examination in the same period were selected as a control group; they (51.23±5.03) years old; both sides were examined. Based on the ABUS imaging, the ultrasound characteristics were observed. The serum levels of VEGF and CEA in both groups were detected using enzyme-linked immunosorbent assay and chemiluminescence. t and χ² tests were used. The receiver operating characteristic curve (ROC) was used to analyze the diagnostic value of ABUS combined with serum VEGF and CEA for breast cancer. Results　The occurrence rates of worm-eaten sign, convergence sign, and stellate sign in the observation group were significantly higher than those in the control group [82.86% (174/210) vs. 23.00% (23/100), 76.19% (160/210) vs. 20.00% (20/100), and 77.62% (163/210) vs. 13.00% (13/100)], with statistical differences (χ²=104.778, 87.840, and 115.262; all P<0.001). The serum levels of VEGF and CEA in the observation group were higher than those in the control group [(141.20±17.23) ng/L vs. (112.81±14.14) ng/L and (8.76±2.92) μg/L vs. (3.51±1.17) μg/L], with statistical differences (t=14.335 and 17.312; both P<0.001). The ROC analysis showed that ABUS combined with serum VEGF and CEA had the highest diagnostic value for breast cancer (AUC=0.981), with a sensitivity of 92.4% and a specificity of 97.0%, which were higher than any single test. Conclusions　ABUS combined with serum VEGF and CEA has a high diagnostic value for breast cancer. Compared with single testing methods, its sensitivity and specificity are higher. It can effectively enhance the early detection and accurate diagnosis of breast cancer.

Key words:

Breast cancer, Automated breast ultrasound system, Vascular endothelial growth factor, Carcinoembryonic antigen, Diagnostic value

田燕袁权王虎霞惠金子段绍雪.

ABUS联合血清VEGF、CEA对乳腺癌的诊断价值 [J]. 国际医药卫生导报, 2024, 30(5): 740-743.

Tian Yan, Yuan Quan, Wang Huxia, Hui Jinzi, Duan Shaoxue.

Value of ABUS combined with serum VEGF and CEA in diagnosis of breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(5): 740-743.

参考文献

[1] 李素玲,鲁江斌.超声自动乳腺全容积成像鉴别诊断乳腺髓样癌、乳腺纤维的价值[J].贵州医药,2023,47(2):285-286.DOI:10.3969/j.issn.1000-744X.2023.02.069.
[2] 陈玉洁.血清Cys-C、VEGF、CA153在乳腺癌诊断中的价值[J].检验医学与临床,2022,19(5):591-593,598.DOI:10.3969/j.issn.1672-9455.2022.05.004.
[3] 李文红,李平法,冯倩倩.血清Cys-C、VEGF、CA153联合检测在乳腺癌早期诊断中的临床价值[J].现代肿瘤医学,2020,28(24):4276-4280.DOI:10.3969/j.issn.1672-4992. 2020.24.013.
[4] 郭红梅,叱强军,王琪,等.自动乳腺全容积成像超声在乳腺癌诊断中的价值[J].实用癌症杂志,2019,34(11):1842-1845.DOI:10.3969/j.issn.1001-5930.2019.11.029.
[5] 陈海萍,包凌云,程颖颖,等.自动乳腺全容积成像冠状面"汇聚征"对乳腺病变的诊断价值[J/CD].中华医学超声杂志(电子版),2018,15(12):948-952.DOI:10.3877/cma.j.issn. 1672-6448.2018.12.012.
[6] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):695-759.DOI:10.19401/j.cnki.1007-3639.2017.09.004.
[7] 王刚,张盼盼,马兆生,等.ABUS联合常规超声在非肿块型乳腺癌中的诊断价值[J].浙江临床医学,2022,24(10):1516-1518.
[8] 李瑞霞,刘娟,王惠,等.常规超声联合自动乳腺全容积成像及超声光散射技术对乳腺癌的诊断价值[J].临床与病理杂志,2022,42(8):1855-1861.DOI:10.3978/j.issn.2095-6959. 2022.08.011.
[9] 王红燕,靳晓娜,姜玉新,等.超声与正电子发射型计算机断层成像技术在乳腺癌诊断及淋巴结评估中的应用[J/CD].中华医学超声杂志(电子版),2017,14(10):743-748.DOI:10.3877/cma.j.issn.1672-6448.2017.10.006.
[10] 王艳,游岚岚.乳腺超声自动容积成像联合超声造影微血管成像在乳腺病灶鉴别诊断及肿瘤TNM分期中的应用价值[J].中国老年学杂志,2020,40(13):2737-2740.DOI:10.3969/j.issn.1005-9202.2020.13.016.
[11] 李晶,张冬梅,王秋杰,等.自动乳腺全容积扫描在乳腺癌患者中诊断效能分析[J].中国实验诊断学,2020,24(10):1642-1644.DOI:10.3969/j.issn.1007-4287.2020.10.017.
[12] 刘翠云,张建华,苏晖.自动乳腺全容积成像在BI-RADS 3类乳腺结节管理中的临床价值[J].内蒙古医科大学学报,2022,44(06):630-633.DOI:10.16343/j.cnki.issn.2095- 512x. 2022.06.019.
[13] 周虹延,马晓丽,冯丽丽,等.ABVS联合二维超声在乳腺癌诊断中的应用[J].新疆医科大学学报,2022,45(4):389-394.DOI:10.3639/j.issn.1009-5551.2022.04.006.
[14] 黄思,肖耀成,李建,等.乳腺自动容积成像对乳腺癌分子分型的预判分析[J].医学研究杂志,2022,51(11):106-109.DOI:10.11969/j.issn.1673-548X.2022.11.022.
[15] 陈照生.血清SDF-1、CXCL5、CEA联合检测对乳腺癌的诊断价值[J].国际医药卫生导报,2020,26(8):1119-1121.DOI:10.3760/cma.j.issn.1007-1245.2020.08.025.
[16] 赵媛媛,王帅力,高晓莉.血清铁蛋白、癌胚抗原、糖类抗原15-3联合检测在乳腺癌诊断、复发转移预测中的价值分析[J].癌症进展,2022,20(9):956-958.DOI:10.11877/j.issn.1672-1535.2022.20.09.23.
[17] 魏小勤,杜伟鹏,翟素平,等.血清癌胚抗原、糖类抗原125、糖类抗原153联合检测对乳腺癌的诊断价值[J].癌症进展,2022,20(23):2465-2467,2472.DOI:10.11877/j.issn.1672-1535.2022.20.23.23.
[18] 何燕.乳腺自动全容积成像在乳腺癌诊断上的临床价值[J].临床与病理杂志,2023,43(3):444-452.DOI:10.11817/j.issn.2095-6959.2023.221827.
[19] 杨建美,王芳,王秀云,等.血清SF、VEGF联合CEA检测在乳腺癌诊断、复发转移预测中的价值[J].分子诊断与治疗杂志,2023,15(5):801-804.DOI:10.3969/j.issn.1674-6929. 2023.05.020.
[20] 和丽丽.血清VEGF、FGF联合乳腺超声诊断乳腺癌的价值[J].河南医学研究,2019,28(21):3975-3977.DOI:10.3969/j.issn.1004-437X.2019.21.076.

ABUS联合血清VEGF、CEA对乳腺癌的诊断价值

Value of ABUS combined with serum VEGF and CEA in diagnosis of breast cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

[1]	张前陈亮杨冉. 3D-CTBA精准定位应用于胸腔镜肺段切除术患者的临床价值 [J]. 国际医药卫生导报, 2024, 30(6): 923-927.
[2]	曹喆霍亚玲王丹. 睾丸肾上腺残基瘤的超声图像特征 [J]. 国际医药卫生导报, 2024, 30(6): 1018-1020.
[3]	丁愫莹李玲玲丁炀. SWI联合DWI在脑出血急性期中的诊断价值 [J]. 国际医药卫生导报, 2023, 29(9): 1272-1275.
[4]	曲其志张敏赵艳玲. 缺血性卒中患者高分辨磁共振血管壁成像特点及价值 [J]. 国际医药卫生导报, 2023, 29(4): 559-564.
[5]	赵昌乾谢丽张敏郭金红. 常规超声联合血清甲状腺球蛋白抗体水平对桥本甲状腺炎的诊断价值 [J]. 国际医药卫生导报, 2023, 29(24): 3571-3575.
[6]	辛秀. 那曲肝素钙联合阿司匹林治疗复发性流产的效果及对患者血清TSP-1、sflt-1水平影响[J]. 国际医药卫生导报, 2022, 28(9): 1288-1292.
[7]	陈斌, 冷志欣, 田红岸. 多层螺旋CT扫描MPR和VR重建在细微及隐匿性骨折中的应用对比[J]. 国际医药卫生导报, 2022, 28(7): 950-953.
[8]	商平平, 于泽, 杨晓平. CST4、CA19-9、CA72-4和CEA联合检验诊断胃癌的价值[J]. 国际医药卫生导报, 2022, 28(5): 715-718.
[9]	刘锦张敏王卉国晓尹春霞. 紫杉醇脂质体联合顺铂治疗晚期卵巢癌患者的疗效及血清肿瘤标志物水平分析[J]. 国际医药卫生导报, 2022, 28(23): 3260-.
[10]	张静. 黄芪甲苷对大鼠肠道缺血再灌注损伤的保护作用[J]. 国际医药卫生导报, 2022, 28(17): 2396-2399.
[11]	史文燕　朱建业　管东东. MRI联合肿瘤标志物在卵巢肿瘤诊断中的应用价值[J]. 国际医药卫生导报, 2022, 28(13): 1778-1783.
[12]	李儒刚, 黄洁平, 张魁正, 何敏, 唐君平, 曾晓琳, 吴慧兰, 陈志强, 梁泽智, 秦小燕, 黄玲. 尿中性粒细胞明胶酶相关脂质运载蛋白对泌尿道感染诊断作用的荟萃分析[J]. 国际医药卫生导报, 2022, 28(10): 1385-1390.
[13]	郭涛, 孟靓靓, 陈晓云, 陈燕, 张承芳. 不同胎龄新生儿和早产儿视网膜病变患儿血管内皮生长因子水平变化分析[J]. 国际医药卫生导报, 2021, 27(6): 840-843.